MICROBIOME NEWS: Fecal transplant turns cancer immunotherapy non-responders into responders.
Researchers at UPMC Hillman Cancer Center and the National Cancer Institute (NCI) demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy—which has a failure rate of 40% for this type of cancer—into patients who do.
Source: MICROBIOME NEWS: Fecal transplant turns cancer immunotherapy non-responders into responders….
I wonder what other cancers this might apply too.
Remember when science said HCQ was useless against Covid-19? Now science says it’s an effective early medical treatment that helped 67 percent of the people to whom it was prescribed. And yes, taking zinc will help stave it off.
Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection – American Journal of Medicine
VOLUME 134, ISSUE 1, P16-22, JANUARY 01, 2021
The currently completed retrospective studies and randomized trials have generally shown these findings: 1) when started late in the hospital course and for short durations of time, antimalarials appear to be ineffective, 2) when started earlier in the hospital course, for progressively longer durations and in outpatients, antimalarials may reduce the progression of disease, prevent hospitalization, and are associated with reduced mortality.
In a retrospective inpatient study of 2541 patients hospitalized with COVID-19, therapy associated with an adjusted reduction in mortality was HCQ alone (hazard ratio [HR] = 0.34, 95% confidence interval [CI] 0.25-0.46, P <0.001) and HCQ with azithromycin (HR = 0.29, 95% CI 0.22-0.40, P <0.001).
Dr. Uri Ben-David of the Sackler Faculty of Medicine at Tel Aviv University, who led the research, told The Media Line that scientists have known for well over a century that malignant cells have an abnormal number of chromosomes. Humans have 46 chromosomes (two sets of 23) but in cancer this number changes because, during cell division, chromosome segregation takes place that can lead to a phenomenon called aneuploidy.
Aneuploidy, the presence of an abnormal number of chromosomes in a cell, not only causes common genetic disorders but is also a hallmark of cancer cells. Not all cancers exhibit aneuploidy, but roughly 90% of solid tumors and 75% of blood cancers do, to a certain degree.
According to Ben-David, the findings open up an entirely new avenue for medical research.
“For decades, we’ve been trying to understand why [aneuploidy] happens in cancer and how it contributes to tumor formation and progression,” Ben-David said. More importantly, he said, scientists have been trying to see “if we can take advantage of this quite unique difference between cancer cells and normal cells in order to selectively kill the cancer cells.”
Scientists found that aneuploid cancer cells were highly sensitive to the perturbation of the mitotic checkpoint — a so-called cellular mechanism which ensures proper separation of chromosomes during cell division.
Source: Jerusalem Post
Source: ISRAEL: Israeli scientists say they’ve found ‘Achilles’ heel’ of cancer cells….
I’ve got aneuploidy all over the place in my cancer — deletions, trisomy, monosomy… apparently no translocations. I’ll be interested to see if anything comes of this.
NOW THEY TELL US: Hydroxychloroquine may have some use to treat COVID after all, NJ study shows. I took it when I had Covid and my case was mild, for whatever that’s worth.
A new Hackensack Meridian Health study shows that people with mild symptoms of COVID-19 may be helped by a controversial drug that had been widely used in the early days of the pandemic before several studies questioned its benefits and safety.
The recently published study looked at a group of people treated as outpatients last year and found that those who received an anti-inflammatory drug, hydroxychloroquine, which is often used for malaria, were significantly less likely to end up in the hospital. Doctors who conducted the study say the findings suggest that it should be tested further.
Source: NOW THEY TELL US: Hydroxychloroquine may have some use to treat COVID after all, NJ study shows. I…
The dengue virus uses a particular protein, called Non-Structural Protein 1 (NS1), to latch onto the protective cells around organs. It weakens the protective barrier, allowing the virus to infect the cell, and may cause the rupture of blood vessels. The research team’s antibody, called 2B7, physically blocks the NS1 protein, preventing it from attaching itself to cells and slowing the virus’s spread. Moreover, because it attacks the protein directly and not the virus particle itself, 2B7 is effective against all four dengue virus strains.
Source: Protection against dengue?
We’re going to see a lot of gains from designer antibodies.
My article for Spectator:
Almost 60 years ago, in February 1961, two teams of scientists stumbled on a discovery at the same time. Sydney Brenner in Cambridge and Jim Watson at Harvard independently spotted that genes send short-lived RNA copies of themselves to little machines called ribosomes where they are translated into proteins. ‘Sydney got most of the credit, but I don’t mind,’ Watson sighed last week when I asked him about it.
The message tells the cell to make part of one of the virus’s proteins which then alerts the body’s immune system. Once invented, the thing is like a general-purpose vaccine. You simply rewrite the message between the same opening and closing sequences, put it in the same kind of bubble, and fire it off — almost as easy for genetic engineers these days as writing a text is for teenagers. It is faster, cheaper, safer and simpler than the old ways of making vaccines.
More conventional vaccine designs may still make a vital contribution to defeating the pandemic, Oxford’s included. And the messenger method has its drawbacks, such as the need for extreme cold storage. But in the long run, messengers probably represent the future of vaccines. Now the principle has been approved by regulators, there may be no need to go through the same laborious and expensive three-phase clinical trials every time. Faced with a truly lethal pandemic — with a 10 per cent mortality rate, say — the vanishingly small likelihood that a new messenger vaccine would be unsafe pales into insignificance. You could deploy it in weeks or days.
What is more, at the cost of a few billion dollars, the world may now be able to build a library of messenger vaccines for every plausible coronavirus and influenza virus with pandemic potential we can find, test them in animals and store the recipes on a hard disk, ready to go at a moment’s notice. Moderna’s vaccine was first synthesised in mid-January, before we even knew the coronavirus was coming out of China.
I’m on a drug which is a monoclonal antibody designed to attack a specific antigen on my cancer. Other treatments involve taking T cells and modifying them so they’ll attack cancer. Why not program a mRNA vaccine to attack those same antigens?
Source: Why mRNA vaccines could revolutionise medicine
WHY IS THE MSM SUPPRESSING FACTS ABOUT HCQ AND COVID? C. Boyden Gray rips apart the Mainstream Media’s coverup of the full facts about the effectiveness of Hydroxychloroquine (HCQ) in treating Covid. “The current accepted press narrative on hydroxychloroquine is that no evidence exists showing it is effective for treating COVID-19, and that it can, in fact, be harmful .
Source: WHY IS THE MSM SUPPRESSING FACTS ABOUT HCQ AND COVID? C. Boyden Gray rips apart the Mainstream Media…
HEALTH: Covid-19 vaccines raise hope for cancer, throw open new field of medicine. The first vaccines against Covid-19 aren’t just a landmark in the fight against the pandemic. They’re also the stepping stone for an unconventional technology that could one day defeat other ailments that have eluded doctors, from cancer to heart disease.
Source: HEALTH: Covid-19 vaccines raise hope for cancer, throw open new field of medicine. The first vacc…
Could this be true ?: Just a few doses of an experimental drug can reverse age-related declines in memory and mental flexibility in mice, according to a new study by UC San Francisco scientists. The drug, called ISRIB, has already been shown in laboratory studies to restore memory function months after traumatic brain injury (TBI), reverse cognitive impairments in Down Syndrome, prevent noise-related hearing loss, fight certain types of prostate cancer, and even enhance cognition in healthy animals.
Source: Could it be? A drug that reverses cognitive decline?
From the FDA report : Two doses is great but one dose already looks good even though sample is small. “ Efficacy against severe COVID-19 occurring after the first dose was 88.9%.” Based on the number of cases accumulated after Dose 1 and before Dose 2, there does seem to be some protection against COVID-19 disease following one dose; however, these data do not provide information about longer term protection beyond 21 days after a single dose.
Source: The Vaccine Works Fast